Featured News
View ASX Announcements here.
Half Yearly Report and Accounts (ASX Announcement)
Feb 28th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Interim Report and Half-Year Financial Results for the period ended 31 December 2023 (H1 FY24).
Read More
VivaGel® BV US FDA Appeal Outcome (ASX Announcement)
Feb 19th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has completed the formal dispute resolution process with the US Food and Drug Administration (FDA) in relation to VivaGel® BV. The FDA has maintained its position that they require additional clinical efficacy data to be generated for the regulatory approval of VivaGel® BV for bacterial vaginosis (BV) in the US. The formal dispute resolution process involved multiple submissions, meetings, detailed analyses, and the preparation of regulatory precedents relating to recent product approvals. Starpharma was supported through this process by highly experienced regulatory advisers, key opinion leaders, and biostatistical and legal advisers, including several who were ex-FDA.
Read More
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Jan 31st, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 December 2023 (Q2 FY24). Starpharma’s closing cash balance as at 31 December 2023 was $32.1 million.
Read More
Viraleze shows antiviral efficacy in COVID-19 patients (ASX Announcement)
Jan 29th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the results of the post-market clinical study of Viraleze™ nasal spray in participants with COVID-19, demonstrating that Viraleze™ reduced SARS-CoV-2 viral load in the nose, increased the rate of virus clearance from the nose, improved key symptoms of COVID-19, including loss of smell (anosmia), and was well-tolerated.
Read More
